CME: Emerging Considerations in Triple Negative Breast Cancer: Focus on Immunotherapy

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy
RestartResume
Although there’s been a lack of targeted therapies for TNBC, immunotherapy-based combination approaches are changing the standard of care.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Immunotherapy-based combination approaches are changing the standard of care for certain patients with triple-negative breast cancer. Dr. Sara Hurvitz and Dr. Tiffany Traina are here to discuss these advances in treatment and what they mean for patient care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:  
    Tiffany Traina, MD
    Associate Attending Physician
    Breast Medicine Service at Memorial Sloan Kettering Cancer Center
    New York, NY

    Consulting Fees: Aduro Biotech, Advaxis, AstraZeneca, Athenex, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech/Roche, Genomic Health, Halozyme, Innocrin Pharma, Merck, Pfizer, Puma Biotechnology, Roche/Genentech Samsung
    Research Funding: Astellas Pharms, AstraZeneca, Carrick Pharm, Daiichi Sankyo, Eisai, Genentech/Roche, Immunomedics, Innocrin Pharma, Novartis, Pfizer

    Sara Hurvitz, MD
    Associate Professor of Medicine
    UCLA
    Los Angeles California

    Contracted Research: Ambrx, Amgen, Bayer, Boerenger Ingelheim, Daiichi Sankyo, Genentech, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, Pieris, Puma, Roche, Sanofi, Seattle Genetics

    Host:
    William Mencia, MD, FACEHP, CHCP
    Vice President of Scientific Affairs
    Global Learning Collaborative
    Ft. Washington, PA

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Samantha Cojocariu has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe unmet needs, molecular heterogeneity of TNBC, and current challenges in its targeted treatment and management.
    • Discuss new insights into the pathobiology of TNBC, including the role of TILs, PD-1, PD-L1, and how these could be harnessed for therapy.
    • Evaluate the utility of recent data from clinical trials in identifying subsets of patients with TNBC for immunotherapy treatment approaches to achieve better outcomes in the first-line setting.
  • Target Audience

    This activity is designed to meet the educational needs of practicing Oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative (GLC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

      

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Global Oncology Academy newsletters.
Comprehensive Oncology Education.

Better education for a better you.

* Required
Optional

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free